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University School of Medicine, New York 10016 
Summary 
Polyreactive antibodies (Abs) constitute a major proportion of the early Ab repertoire and are 
an important component ofthe natural defense mechanisms against infections. They are primarily 
immunoglobulin M (IgM) and bind a variety of structurally dissimilar self and exogenous antigens 
(Ags) with moderate affinity. We analyzed the contribution of Ig polyvalency and of heavy (H) 
and light (L) chain variable (V) regions to polyreactivity in recombinatorial experiments involving 
the V.-diversity(D)-JH and VK-J~ gene segments of a human polyreactive IgM, monoclonal 
antibody 55 (mAb55), and those of a human monoreactive anti-insulin IgG, mAb13, in an in 
vitro Cyl and C~ human expression system. These mAbs are virtually identical in their V, and 
VK gene segment sequences. First, we expressed the V.-D-J. and V~-J~ genes of the IgM mAb55 
as V segments ofan IgG molecule. The bivalent recombinant IgG Ab bound multiple Ags with 
an efficiency only slightly lower than that of the original decavalent IgM mAb55, suggesting 
that class witch to IgG does not affect he Ig polyreactivity. Second, we coexpressed the mAb55- 
derived H or K chain with the mAb13-derived K or H chain, respectively. The hybrid IgG Ab 
bearing the mAb55-derived H chain V segment paired with the mAb13-derived ~ V segment, 
but not that bearing the mAb13-derived H chain V segment paired with the mAb55-derived 
K V segment, bound multiple Ags, suggesting that the Ig H chain plays a major role in the 
Ig polyreactivity. Third, we shuffled the framework 1(FR1) -FtL3 and complementarity determining 
region 3 (CDR3) regions of the H and K chain V segments ofthe mAB55-derived IgG molecule 
with the corresponding regions of the monoreactive IgG mAb13. The mAb55-derived IgG molecule 
lost polyreactivity when the H chain CDR3, but not the FR1-FR3 region, was replaced by 
the corresponding region of mAb13, suggesting that within the H chain, the CDR3 provides 
the major structural correlate for multiple Ag-binding. This was formally proved by the multiple 
Ag-binding of the originally monoreactive mAb13-derived IgG molecule grafted with the mAb55- 
derived H chain CDR3. The polyreactivity of this chimeric IgG was maximized by grafting 
of the mAb55-derived K chain FK1-FIL3, but not that of the K chain CDK3. The mAb55-derived 
K chain FR1-FK3 (an unmutated V~ 325 segment), however, failed to yield a polyreactive Ab 
when grafted onto an IgG that was in all other parts identical with mAb13. Rather, this chimeric 
molecule showed full specificity for insulin. Thus, the polyreactivity of the human mAb55 can 
be fully preserved after Ig class switch, and depends primarily on the contribution of structures 
that are generated through somatic rearrangement events (H chain CDK3), and structures that 
represent the expression of an unmutated gene (VK 325 segment). 
S era of healthy humans and animals contain natural anti- bodies (Abs) that react with a variety of self and exoge- 
nous Ags. Most natural mAbs generated from humans and 
mice are polyreactive, i.e., they bind multiple, even very het- 
erogeneous, Ags such as polysaccharides, nucleic acids, haptens, 
and proteins, including structural cellular and tissue compo- 
nents and soluble hormones, generally with moderate intrinsic 
affinity (for a review see reference 1). Because of their broad 
reactivity with exogenous Ags, natural Abs may play a major 
role both in defense against invading bacteria or viruses be- 
fore specific Abs are generated, and in clearance of cellular 
debris and certain toxic substances. Because of their reactivity 
with various self Ags, including DNA, IgG Fc fragment, 
and phospholipids, natural Abs may serve as templates for 
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some of the high-affinity autoantibodies merging in patients 
with autoimmune disease. 
The multiple Ag-binding activity and primordial Ig class, 
mainly IgM, of natural Abs contrast with the exquisite 
specificity and mature Ig class, mainly IgG, of the Ag-induced 
Abs. Despite their moderate intrinsic affinity, polyreactive 
Abs generally display a high avidity for Ag due to the 
decavalency ofthe predominant IgM class. Consequently, their 
effectiveness in binding Ag would be expected to decrease 
dramatically, because of a decrease in overall avidity, after Ig 
class switch and substitution of a 3' for a # H chain (2). The 
characteristic spectra of Ag-binding activities of polyreactive 
Abs presumably reflect fundamental differences in the struc- 
ture of their Ag-binding sites, as compared to those of Ag- 
induced (monoreactive) specific Abs, although the limited 
molecular data available have failed to yield definitive clues 
to such differences (3-12). It has been suggested that poly- 
reactive Abs rely on the utilization of selected V. genes, pos- 
sibly in unmutated configuration, for the recognition of mul- 
tiple Ags (1, 11, 12). However, recent data have shown that 
these Abs use various arrays of different V. and V~ gene seg- 
ments, as well as different D, Jtt, and/or J~ gene segments, 
suggesting that the somatically generated H chain CDR3 
may provide the crucial structural correlate for multiple Ag- 
binding (6, 13, 14). 
To analyze the contribution of different Ig V regions to 
polyreactivity and to assess the impact of class switch to IgG 
on the ability of an originally polyreactive IgM Ab to bind 
multiple Ags, we performed recombinatorial experiments in- 
volving a human polyreactive IgM, mAb55 (3) and a human 
monoreactive anti-iiasulin IgG, mAb13 (15). These two mAbs 
were chosen because they use the same V. and V~ gene seg- 
ments in a highly similar configuration and with highly 
conserved FR structures (7, 16). Analysis of the chimeric 
molecules generated by replacing different portions of the 
polyreactive mAb55 H and L chain V segments with the 
corresponding portions of the monoreactive mAb13 and by 
expressing the "wild-type" or recombinant H and L chain 
V gene segments juxtaposed with the same Cyl and C, 
chains, respectively, demonstrating that Ab polyreactivity was 
not affected by class switch from IgM to IgG and was depen- 
dent on the structure of the H chain CDR3 and that of the 
unmutated V~ 325 framework 1 (FR1) 1 -FR3 segment. 
Materials and Methods 
Cloning and Sequencing ofthe V,,-D-J, and VJ~ Genes of mAb55 
and mAbl3. The polyreactive IgM ~, mAb55, and the monore- 
1 Abbreviations u ed in this paper: Avrd, relative avidity (g//~l); ds, double 
stranded; FR, framework region; IDDM, insulin-dependent (type I)diabetes 
mellitus; ss, single stranded. 
active anti-insulin IgG K, mAbl3, were generated by EBV trans- 
formation and somatic ell hybridization techniques u ing periph- 
eral B cells from a healthy subject and a patient with insulin- 
dependent diabetes mellitus (IDDM), respectively (3, 15). IgM K 
mAb55 was shown to be at least pentameric by size fractionation 
analysis on a Superose 12 column (Pharmacia LKB Biotechnology, 
Piscataway, NJ). 
The sequences of the mAb55 V.-D-J., mAb13 V.-D-J., and 
mAb13 V~-J~ gene segments have been reported (7, 16); that of 
the mAb55 V.-J. gene segment was derived for the purpose of 
these studies using described procedures (7-10). These sequences 
are depicted in Fig. 1 A, and are summarized in Table 1. The two 
mAb V. gene sequences were 96.4% identical throughout the 
coding area, differing from that of the germline Hll gene (17) in 
five (mAb13) and nine (mAb55) nucleotides. Both mAbs utilized 
the DXP'I gene (18) but in different reading frames, and com- 
plemented by different unencoded nucleotides and different trun- 
cated J. genes (19). The sequences of the mAb55 and mAb13 V.III 
genes were 93.8% identical throughout the coding area. The mAb55 
V~ gene sequence was identical to that of the germline kv325 gene 
(20) except for a silent T ~ G change at position 288; that of the 
mAb13 V. gene differed in six nucleotides from the sequence of 
the germline kv3g gene (21). Both mAbs used a JA gene (22), 
Expression Vectors. The pcDNAIG and pSXRDIG plasmid 
vectors (23) were used for the in vitro expression of the human 
Ig V.-D-J. and V,-J. gene segments, respectively, pcDNAIG is a 
mammalian expression vector derived from pcDNAI/Neo (In- 
vitrogen Corp., San Diego, CA) (Fig. 2 A). It encodes a human 
CMV promoter, amurine leader sequence, a whole human IgG1 
H chain, and a Rous sarcoma virus (RSV) LTR-driven neomycin 
resistance gene. pSXRDIG is a mammalian expression vector de- 
rived from pUC18 (Fig. 2 B). It contains aSV40 promoter, amu- 
rine leader sequence, a whole human Ig K L chain, and a DHFR 
gene for selection by methotrexate, 
Introduction of mAb55 and mAbl3 V.-D-J,, Gene Segments into 
pcDNAIG Vector. The unique HindlIl and XhoI sites, 5' and 3" 
respectively, of the leader-V.-D-J, gene segment in pcDNAIG 
were utilized for the introduction of the rearranged mAb55 or 
mAb13 V.-D-JH gene segment (Fig. 2 A). The mouse H chain 
leader sequence of pcDNAIG and the V.-D-J. gene segment of 
mAb55 (or mAbl3) were amplified in separate PCRs (PCR 1 and 
PCR 2), and joined by "recombinant" PCR to yield the recom- 
binant "leader-mAb55 (or mAb13) V.D-JH" gene segment (Fig. 
3 A), using the sense H-leader (5' gggaagcttctcaccatgggatgg 
3') and the antisense H-Ovl (5' GCTGCACCTCacactggacacctg- 
cagagaaag 3') primers; and the sense H-Ov2 (5' ttctctgcaggtgtc- 
cagtgtGAGGTGCAGCTG 3') and the antisense H-FR4 (5' 
gggctcgagactcaccTGAGGAGACGGTAACCG 3' formAb55 J.6 or 
5'gggctc~aI~actcaccTGAGGAGACAGTGACCA 3' for mAb13 J.2) 
primers (uppercase letters denote the sequences derived from the 
Ig V gene sequence ofmAb55 or mAb13; lowercase l tters denote 
the sequences derived from the expression vectors; sequences of
restriction sites are underlined). The sequences of the primers used 
at the ends to be joined (H-Ovl and H-Ov2) were complementary 
and allowed for partial annealing of the PCR 1 and PCR 2 prod- 
ucts and performance ofa recombinant PCR by addition of excess 
Figure 1. Nucleotide (A) and deduced amino acid (/3) sequences of the V., D-J., V., and J, gene segments ofmAb55 and mAb13. The top se- 
quence in each duster is that of the germline gene to which the remaining sequences of the cluster were compared. Dashes indicate identities. Solid 
lines on the top of each cluster depict CDRs. Dots represent deletions. Lowercase l tters denote untranslated sequences. The sequences ncompassed 
by the GIII-FR3 and IdII-FR3 primers are underlined. The present sequences are available from EMBL/GenBank/DDBJ under accession numbers 
1.08084, b32748, D-16833, and D-16834. 
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Figure 2. Structure ofthe pcDNAIG (.4) and pSXRDIG (B) expres- 
sion vectors. The segment between HindIII and XbaI sites, comprising 
the Ig H or g chain gene is detailed. Boxes indicate xons: (Shaded boxes) 
mouse leader exons; (open boxes) human Ig V chain gene xons (hatched 
boxes) human Ig C chain gene xons. Solid lines indicate introns and non- 
coding sequences. (CoIEI) ColE1 origin bases; (DHFR) dihydrofolate reduc- 
tase gene for methotrexate selection; (HBS pA) HBV surface antigen Poly(A) 
site; (L.) mouse H chain leader sequence; (L~) mouse Kleader sequence; 
(MI3 ori) M13 origin bases; (P CMI O human CMV promoter; (P SV40) 
SV40 promoter; (RSVLTR) RSV LTR sequence; (supF) supF suppressor 
tRNA gene; (SV40 Polyoma ori) SV40 origin bases and polyoma origin 
bases; (SV40 splice/ply A site; (Neomycin) eomycin resistance g ne. 
H-leader and H-FR4 primers (Fig. 3 A). The recombinant frag- 
ment was sequenced, to ensure that no unintended mutations were 
introduced during PCR amplification (8, 10, 16, 24), digested with 
HindlII and XhoI, ligated into pcDNAIG previously digested with 
HindlII and XhoI and freed of its original Va-D-J. gene segment. 
The recombinant pcDNAIG plasmids were amplified by transfor- 
mation of competent MC1061/P3 cells (Invitrogen Corp.), and se- 
lection with ampicillin and tetracycline. Plasmid DNA was iso- 
lated using a plasmid kit (Qiagen Inc., Chatsworth, CA). 
Introduction of mAb55 and mAbl3 V.-J. Gene Segments into 
pSXRDIG Vector. The unique HindlII and XhoI sites, 5' and 3" 
respectively, of the leader-V.-J, gene segment in pSXRDIG, were 
utilized for the insertion of the mAb55 or mAb13 V.-J~ gene seg- 
ment (Fig. 2 B). The routine K-leader sequences ofpSXRDIG and 
the mAb55 (or mAb13) V~-J. gene segment were amplified in sep- 
arate PCRs and joined by recombinant PCR (Fig. 3 A). The se- 
quences of the primers used for these PCRs were as follows: sense 
It-leader (5' gggaagcttatcaagatgaagtca 3'), antisense K-Ovl (5' 
CAACACAATTTCgcatctggaacctgcagtcagaga 3'); sense K-Ov2 (5' 
gcaggttccagatgcGAAATTGTGTTGACGCAGTCT 3'), antisense 
K-FR4 (5'gggctcgagacttacgTTTGATCTCCACCTTGG 3'). The 
recombinant fragment, leader-mAb55 V~-J. or leader-mAb13 V~- 
J., was inserted into pSXRDIG after digestion with HindlII and 
XhoI. Recombinant pSXRDIG plasmids were amplified in com- 
petent DH5c~ cells by selection with ampicillin. 
Construction fRecombinant (rec)V.13-55 and recV.55-13 Gene Seg- 
ments, The method used to construct the recV.13-55 gene seg- 
ment is schematized in Fig. 3 B, The sequence ncoding the leader 
through the FR3 area of mAb13 H chain V segment was PCR 
amplified using the sense H-leader and antisense GIII-FR3 B (5' 
CGGCTCTCAGACTGTTCATTGC 3') primers (Fig. 1 A). The 
sequence ncoding the FR3 though FR4 area of mAb55 H chain 
V segment was PCR amplified using the sense GIII-FR3 A (5' 
GCAATGAACAGTCTGAGAGCCG 3') (the reverse complement 
of GIII-FR3 B) and the antisense H-FR4 primers. The two amplified 
fragments were purified and joined by recombinant PCR. The same 
primers, except for the H-FR4 primer, and recombinant PCR were 
used for the construction of the recV.55-13 gene segment. The 
recV.13-55 and recV.55-13 gene segments were introduced into 
pcDNAIG as described above. 
Construction of recV.13-55 and reeve55-13 Gene Segments. The 
A 
Express ion vector  
B 
mAb55 cDNA Leader -mAb13 V(D)J  segment  Leader -mAb55 V(D)J  segment  
Hind 11[ X~o l X]~o I Hind Ill 
5' ~ leader - - ;~-  V(D)J ~ I ~ V(D)J ~ / 5,~lleader , 
- -  - -  5 . . . . . . . . . . . .  "~"--~'-~'.~X~"/3' 
--~-o-r 3. ,.~,~23. " -~;~, '~5.  ~ 
3 ' ~  m 5' 3 . . ,~ ,~H.T ; , ,  . . . . . . .  ~;7.... 5' 3'~ 
PCR1NN~ / PCR 2 
leader 
5' =~IHHHH,'SH~HHH//,'~=r 3' 
3' =r 
Recombinant PCR (with leader and FR4 primers) 
llind IIl X~o I flind III 
1 leader V(D)J ] leader 
s '~  ~ . . . . . . . . . . . . . . . . . . . . . .  . t~  3' ~, 
3' ~1 rHH~HHHHHHJ~p~r 5' 2 I 
Leader -mAb55 V(D)J  gene segment  
Xho 1 Hind IlI 
V { (D)JI l ]pleader 
~ 3,5, r l  
- -  - -~  3' FR3B 
~ 5' 3 '~ 
PCR lX~ 
leader 
5 '~ 
3, ~ I 
Xho 1 
,.....v . . . . . .  ~.c.%~3. 
,.F,2.~.% ~ ,' 
aS '  
V /PCR 2 
,.o3, 
--, 5' (O)J 
5' *IH~ pH/~ 3' 3, ;ZY.Z';~ 5, 
Xho 1 
V (D)J j 
. . . .  f .H . . .~  3' 
. ./11H~///..a~ 5' 
Chimeric V13-55 gene segment 
F igure  3. (A) Construction of 
the recombinant "mouse leader- 
human mAb55V-(D)-J" gene seg- 
ment (leader-mAb 55V.-D-J. or 
leader-mAb 55 V.-J.). Solid (m), 
shaded (m), and hatched (rio lines 
depict he sequences of the expres- 
sion vector (pcDNAIG or 
pSXRDIG), that of the V-(D)-J 
gene segment tobe substituted, and 
that of the V-(D)-J gene segment 
of mAb55, respectively. (Broken 
arrows) Nucleotide chain elongation 
by DNA polymerase. (Open boxes) 
Restriction sites. The mouse leader 
Ig V gene segment in the expres- 
sion vector and the V.-D-J. or V.- 
J~ gene segment of mAb55 were 
amplified in separate PCR (PCR 1 
and PCR 2), and joined by recombinant PCR. Primers used at the end to be joined (primers Ovl and Or2) were made complementary to one another 
by including nucleotides atthe 5' end that are complementary to the 3' portion of the other primer (see Materials and Methods). Primers "leader" 
and "FR4" were designed to )field final recombinant products bearing HindllI and Xhol sites used for the introduction i to the expression vectors. 
(/3) Construction of the chimeric V13-55 (recV.13-55 or recV~13-55) gene segment. Gene segments amplified from the recombinant leader-mAb 13-V- 
(D)-J gene sequence by the leader and FR3 B primers (PCR 1), and amplified from the recombinant leader-mAb 55V-(D)-J gene sequence by the 
FR3 A and FR4 primers (PCR 2) were joined by recombinant PCR. See Materials and Methods for the sequences ofthe sense FR3 A (Gill FR3 
A and Ir FR3 A) and the antisense FR3 B (Gill FR3 B and Kill FR3 B) primers. 
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method used to construct the recVA3-55 and recV~55-13 gene seg- 
ments was similar to that used for construction of the recV, seg- 
ments (Fig. 3 B). The sequence encoding the leader though the 
FR3 area of mAb13 and mAb55 r V segment was PCK amplified 
using the sense r-leader and antisense r,/II-FR3 B (5' GCTGACAG- 
TAATACACTGCAAAATCTTC 3') primers (Fig. 1 A). The se- 
quence ncoding the FR3 though FR4 area of mAb55 or mAb13 
r V segment was amplified using the sense gUI-FR3 A (5' GAA- 
GATTTTGCAGTGTATTACTGTCAGC 3') (reverse complement 
of rIII-FR3 B) and antisense r-FR4 primers. For each pair of seg- 
ments, the two amplified DNAs were purified, joined by recom- 
binant PCK, and introduced into pSXRDIG. 
Cell Culture and Transfection. Mammalian F3B6 cells were used 
in all transfection experiments. F3B6 is the Ig nonsecretor human- 
mouse heterohybridoma used as fusion partner for the genera- 
tion of mAh13 and mAb55 (3, 15). F3B6 cells were cultured in 
RPMI-1640 (BioWhittaker, Walkersxdlle, MD) with 10% FCS, 1% 
L-glutamine, and antibiotics (FCS-RPMI), washed, and then 
resuspended in FCS-RPMI at 107/ml. The cell suspension (750/~l) 
containing pcDHAIG (4/zg) and FSXRDIG (4/~g) vector DNA 
was transferred into an ice-cold electroporation cuvette with a 0.4-cra 
gap (Invitrogen Corp.). After application of an electric pulse of 
750 V/cm with a capacitance of 1,000 IzF using the Elec- 
troporator TM (Invitrogen Corp.) and a power supply (model 4000; 
GIBCO BRL, Gaithersburg, MD), the cuvette was kept on ice 
for 10 min. Ceils were then transferred toa flask containing 10 
ml of tavwarmed FCS-RPMI. After a 48-h culture, cuhare medium 
was changed to selective medium containing 0.4 mg/ml of G418 
(Genetidn; GIBCO BRL), and cells were distributed into 96-well 
flat-bottom plates. Neomycin only was used as selecting agent, be- 
cause in transfectants expressing only pcDNAIG (H chain), the 
accumulation f unsecretable H chain molecules leads to cell death. 
Clumps of transformant cells were detected within 7-10 days. After 
2 wk, culture fluids were tested by ELISAs using plates coated with 
goat F(ab')z fragment specific to human Ig # + 7 + c~ H chains. 
Double y1 and r chain producer cells were identified by developing 
separate ELISA plates with peroxidase-conjugated affinity-purified 
goat anti-human Igy and r chain probes (Cappel, Organon Teknika 
Corp., Durham, NC) (3-5). In each transfection, 5 -12 clones 
secreting I G r were generated. The three most efficient secretors 
were expanded and frozen. 
Ab Purification, Binding Assays, and Measurement of Relative Avidity 
(Av,a). IgG mAbs were purified from culture supernatant by 
50% ammonium sulfate precipitation followed by absorption of 
the solubilized IgG onto a GammaBind G-Sepharose column (Phar- 
macia LKB Biotecbnology), and elution with 100 mM glycine- 
HC1 buffer (pH 2.7). Eluates were brought to pH 7.5 by addition 
of neutralizing buffer (pH 9.0), dialyzed against PBS, and stored 
in aliquots at 4~ mAb binding to human recombinant insulin 
(Eli Lilly Research Laboratories, Indianapolis, IN), single stranded 
(ss)DNA, human recombinant IL-13 (BASF Biotech Corp., Worces- 
ter, MA), polyclonal human IgG Fc fragment, etanus toxoid, and 
BSA was measured using appropriate ELISAs (3-5). IgG bound 
to solid-phase IgG Fc fragment were measured using a peroxidase- 
conjugated, affinity-purified goat anti-human Ig r chain probe 
(Cappel, Organon Teknika Corp.). Binding of mAbs to soluble 
insulin was measured bycompetitive ELISA (3-10, 15, 16). Briefly, 
increasing amounts (0.25-100 #g) of soluble insulin were mixed 
with a constant amount of Ab in 100/zl of PBS containing 0.05% 
Tween 20 (PBS-Tween) and 1% BSA. After an 18-h incubation at 
room temperature, the mixtures were transferred into ELISA plates 
precoated with insulin. After a 1-h incubation and subsequent 
washing with PBS-Tween, the amount of Ab bound to the solid- 
phase insulin was measured. For each Ab, the binding measured 
after incubation under identical conditions but in the absence of 
soluble iasalin (always >1.00 OI) at 492 rim; negative control 
<0.04) represented 100% binding activity. The concentration (g/#l) 
of sohble insulin fielding 50% inhibition of Ab binding to solid- 
phase insulin was used to express the Av~. 
Results 
Structure and Specificity of the Human PdFeactive mA b 5 5 and 
Monoreactive mAb13. To define the relative contribution of 
the whole Ig H and L chain V segments and/or their discrete 
regions of polyreactivity, we generated a variety of chimeric 
Ig molecules by replacing different portions of polyreactive 
mAb55 H and r chain V segments with the corresponding 
portions of monoreactive mAbt3, mAb55 is a "prototypic" 
natural haman Ab in that it was ~.tmrated from a healthy 
subject, and is a polyreactive IgM with moderate affinity for 
various ligands (3). The anti-insulin mAhl3 is a prototypic 
Ag,-indmed "mature" human aumanfibody~ that it stemmed 
by affinity maturation from the iastflin-stmcific autoantibody 
response in a patient with IDDM, andis a monoreacfive and 
highly specific [gG (21, 22). Deduced amino acid u:qtumces 
of mAb$5 and mAb13 V,-~D-J, genes were 94.9% identical 
throughout the V= area, differing in four amino acids in the 
CDKI and CDK2 and one amino acid in the FR3, but were 
highly divergent in length and composition of the somati- 
cally generated CDR3 (Fig. 1 B). The two mAb H chain 
FK4 sequences differed only in two amino acids. The two 
mAb V,III segment sequences were 87.6% identical, 
differing in four amino acids (including one deletion) in the 
CDK1 and CDK2 and seven in the FKs (Fig. 1 B). The 
mAb55 Vr segment represented the expression of an unmu- 
tated Vr325 gene. The two mAb r chain CDK3s were iden- 
tical in length, but differed in five of the nine amino acids. 
The r chain FK4 sequences were identical. 
Thus, mAb55 and mAb13 were highly similar or identical 
in their V., H chain FK4, V~ and r chain FR4 segments, 
but substantially different in their H chain CDK3S, and, to 
a lesser extent, r chain CDR3s. The mAb55 and mAb13 dose- 
saturable bindings to human insulin, human IL-1/3, ssDNA, 
human IgG Fc fragment, etanus toxoid, and BSA are depicted 
in Fig. 4, A and C. The mAb55 Avr,i for human recom- 
binant insulin, used as a measure of the mAb ability to bind 
Ag in the fluid phase, was approximately two orders of mag- 
nitude lower than that of mAb13 (Table 1). 
Effect of Class Switch on mAb55 Polyreactivity. Decavalency 
has been claimed to be an important factor in IgM polyreac- 
tivity. To verify whether the pentameric structure of the 
mAb55 is in fact a major determinant of the ability of this 
Ab to bind multiple Ags, we juxtaposed the mAb55-derived 
V,-D-J, and V,-JK gene segments with human Cy1 and CK 
genes, respectively, byrecombination i to the Cy1 pcD-NAIG 
and C~ pSXRDIG vectors, and expressed them by simul- 
taneous transfection ofF3B6 cells. 10 stable transformant clones 
secreting human lgG1 r were generated, three of which were 
expanded to produce recombinant mAb55 IgG1 r molecules 
(designated reclgG55). The purified monomeric reclgG55 Ab 
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Figure 4. Binding of the original ]gM r mAb55 (A), reclgG55 (B), original IgG r mAb13 (C), reclgG13 (D), recV.55-55/recV~13-13 (E), recV.13- 
13/recV~55-55 (F), recV.13-55/recV~55-55 (G), recV.55-13/recV~55-55 (H), recV.13-55/recV,13-13 (/), recV.13-55/recV~13-55 (]), recV.13-55/recV~55- 
13 (K), and recV.13-13/recV~55-13 (L) antibodies to human recombinant insulin (1), ssDNA (A), tetanus toxoid (m), human recombinant IL-1/3 
(A), human IgG Fc fragment (O), and BSA (F3). Bars below each panel scbematize the composition of each original or recombinant antibody. (Open 
boxes) Human C? and CK segments; and (shaded boxes) human C# segments. (Hatched boxes) The V segments derived from the polyreactive mAb55; 
(open boxes) those derived from the monoreactive anti-insulin IgG mAb13. The Ag-binding activity of each antibody isexpressed as optical absorbance 
at 492 nm. 
Table 1. Structure and Properties of Human mAb55 and mAb13 
Chains 
Av~a for 
Clone Source H L Reactivity insulin 
V~ segment V~ segment 
V. gene D gene J. gene V, gene J~ gene 
mAb55 Healthy subject # K Polyreactive 5.0 x 10 -7 
mAb13 IDDM patient "/1 K Monoreactive 
(anti-insulin) 
4.9 x 10 -9 
Hll* DXP'I* J.6S kv3251h J,11 
(VAIl) 
Hl l  DXP'I J.2 kv3g** JA 
(V~m) 
* The sequence of the germline Hll gene has been reported by Rechavi et al. (17). 
t D genes have been reported by Ichihara et al. (18). 
S J, genes have been reported by Ravetch et al. (19). 
II The sequence ofgermline kv325 gene has been reported by Kipps et al. (20). 
82 Jr genes have been reported by Heiter et al. (22). 
** The sequence ofgermline kv3g gene has been reported by Pech et al. (21). 
bound in a dose-saturable fashion and with an efficiency only 
slightly lower than that of the original pentameric IgM mAb55 
to the six self and exogenous Ags tested (Fig. 4, A and B). 
This slightly lower multiple Ag-binding efficiency was 
reflected in a slightly lower Avra for insulin of the reclgG55 
when compared with its IgM counterpart (8.5 x 10 -7 vs. 
5.0 x 10 -7 g//A). These experiments show that class switch 
from IgM to IgG does not significantly affect he ability of 
mAb55 to bind multiple Ags, and that polyreactivity is a 
function inherent o the V portion of the Ig molecule. 
Contribution of the mAb55 V,-D-J, Segment toPolyreac- 
tivity. To evaluate the relative contribution of the whole 
V.-D-J. and V~-J~ segments to the polyreactivity of the 
reclgG55 Ab, we first inserted the V,-D-JH and V,-J, gene 
segments derived from mAb13 into the C3,1 pcDNAIG and 
C, pSXRDIG vectors, respectively, and simultaneously ex- 
pressed the recombinant Ig chains by transfection of F3B6 
cells. Pairing of the recombinant H and K chains yielded a 
fully functional molecule, designated reclgG13, which bound 
insulin in a dose-saturable fashion and with an efficiency com- 
parable to that of the original mAb13 (Avra for insulin was 
7.5 x 10 -9 g//zl, compared with 4.9 x 10 -9 g//zl for 
mAb13) but none of the other Ags tested (Fig. 4, C and D). 
Having shown that the expression ofmAb55 and mAb13 V 
gene segments juxtaposed with the same Cy l  and CK genes 
in a recombinant system did not essentially alter the distinct 
original Ag-binding features of the two mAbs, we constructed: 
(a) the hybrid IgG molecule recV.55-55/recVA3-13 bearing 
the mAb55-derived H chain V segment and the mAb13- 
derived K chain V segment, and (b) the hybrid IgG molecule 
recV.13-13/recV~55-5 bearing the mAb13-derived H chain V 
segment and the mAb55-derived x chain V segment. Although 
somewhat less efficiently (Avro~ for insulin, 1.2 x 10 -6 
g//xl), the recV.55-55/VA3-13 hybrid Ab bound multiple 
Ags in a fashion similar to that of the reclgG55 (recV.55- 
55/recV~55-55) and the original polyreactive IgM mAb55 
molecules (Fig. 4, E,/3, and A). In contrast, the recVa13- 
13/recV~55-55 hybrid Ab did not bind any of the Ags tested 
(Fig. 4 F). The failure of this Ab to bind insulin may have 
been due to a "damping" effect by the recV,55-55 segment 
on the inherent insulin specificity of the recV.13-13 seg- 
ment, since the recV.13-13 segment showed full expression 
of insulin specificity (Ichiyoshi, Y., M. Zhou, and P. Casali, 
manuscript submitted for publication) when paired with the 
Vr segment of mAbl0 (14) which is very different in se- 
quence from the Vr segment of mAb13 or mAb55. This 
phenomenon is reminiscent of the finding by Radic et al. 
(25) who showed that the H chain of murine anti-DNA 3H9 
Ab contains most or all of the required eterminants for double 
stranded (ds)DNA binding, but its pairing with certain L 
chains can result in abrogation of this binding. Thus, the 
mAb55 V,-D-J. segment is necessary and sufficient for mul- 
tiple Ag-binding. 
Role of the H Chain CDR3 in mAb55 Polyreactivity. To 
determine whether mAb55 polyreactivity rests in the V, 
segment itself (Flkl through FIL3 sequence) or the somati- 
cally generated H chain CDR3, we evaluated the functional 
role of the discrete V. segment and CDR3, using: (a) the 
recV.13-55 gene segment, constructed by juxtaposing the 
mAb13-derived V. sequence with the mAb55-derived D-J, 
sequence; and (b) the recV.55-13 gene segment, constructed 
by juxtaposing the mAb55-derived V. sequence with the 
mAb13-derived D-J. sequence. In these gene recombina- 
tions, the last residue of the V. FR3, which is a Val in 
mAb55 and an Arg in mAb13, was regarded as part of the 
CDR3, because FR residues adjacent o CDR might con- 
tribute to the conformation of the CDR loop itself (26). The 
two chimeric gene segments were inserted into the Cyl 
pcDNAIG vectors, and separately expressed by transfection 
of F3B6 cells along with the VK-JK gene segment derived 
from the polyreactive mAb55 (recVK55-55) to yield the 
recV.13-55/recVK55-55 and recV.55-13/recV~55-55 Ab mol- 
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ecules. Consistent with the role of the H chain CDR3 in 
providing the structural correlate for polyreactivity, the 
recV.13-55/recV~55-55, butnot the recV.55-13/recV~55-55, 
IgG Ab bound multiple Ags (Fig. 4, G and H). In fact, the 
extent o which the recV.13-55/recV~55-55 molecule bound 
to the Ags tested was comparable (AV=I for insulin, 9.4 x 
10- 7 g//zl) to that of the reclgG55 and that of the original 
IgM mAb55 (Fig. 4, B and A), Thus, the CDR3, not the 
V. segment, is the crucial element providing the structural 
correlate for the polyreactivity displayed by the mAb55 H 
chain. This contention was further strengthened by the 
demonstration that grafting of the mAb55-derived H chain 
CDR3 onto a molecule which was in all other parts iden- 
tical to mAb13 enabled the molecule to bind multiple Ags. 
The Ab resulting from the pairing of the recV,13-55 gene 
segment with the recVA3-13 gene segment bound to all Ags 
tested, although less efficiently, in a fashion similar to that 
of the recV,55-55/recVA3-13 hybrid molecule, which was 
encoded by the whole arm mAb55-derived V.-D-J. gene 
segment (Fig. 4, I and E). 
Role of the V~ Segment in mAb55 Polyreactivity, Analysis 
of the recV.13-55/recVA3-13 molecule mphasized the role 
of the H chain CDR3 in Ag-binding. It also indicated that 
the mAb55 K chain contributed to polyreactivity. This was 
initially suggested by the slightly suboptimal binding to mul- 
tiple Ags displayed by the recV.55-55 segment paired with 
the recVA3-13 segment (Fig. 4 E). To determine which por- 
tion of the mAb55 VK chain was synergistic with the H 
chain in binding Ags, we substituted the V~ FR1-FR3 or 
K chain CDR3-FR4 sequence of the recV.13-55/V~13-13 
molecule with the respective corresponding sequences derived 
from mAb55. To this end, we constructed: (a) the recV,13-55 
gene segment, by juxtaposing the mAb13-derived VK se- 
quence, encoding the FR1-FR3, with the mAb55-derived 
V~-J~ sequence, encoding the CDR3-FR4; and (b) the 
recV~55-13 gene segment, by juxtaposing the mAb55- 
derived V~ sequence, encoding the FR1-FR3, with the 
mAb13-derived V~-J, sequence, ncoding the CDR3-FR4. 
The two chimeric gene segments were inserted into the C~ 
pSXRDIG vectors, and separately expressed by transfection 
of F3B6 cells as paired with the recV.13-55 gene segment, 
to yield recV.13-55/recVA3-55 and recV.13-55/recV~55-13 
molecules. Grafting of the mAb55-derived V~FR1-FR3 se- 
quence, but not the K chain CDR3-FR4 sequence, onto the 
L chain of the recV.13-55/recVA3-13 molecule significantly 
enhanced the multiple Ag-binding activity of this Ab (Fig. 
4, K and J). In fact, the recV.13-55/recV~55-13 molecule 
bound multiple Ags with an efficiency (Av=l for insulin, 8.4 
x 10 -7 g/#l) comparable to that of the integral reclgG55 
Ab (Fig. 4 B). The germline configuration of the mAb55- 
derived V,325 FR1-FR3 segment is crucial in Ag-binding 
by the autologous H chain CDR3, but may not be sufficient 
to independently provide a structural correlate for polyreac- 
tivity, as grafting of the mAb55-derived V~ gene segment 
onto a molecule ncoded in all other parts by mAb13-derived 
gene segments failed to generate a polyreactive Ab. Instead, 
this Ab, recV.13-13/recV~55-13, bound specifically to insulin 
but to none of the other Ags (Fig. 4 L). Its exquisite specificity 
for insulin (Av=l, 6.0 x 10 -9 g/#l) was comparable to that 
measured for reclgG13 and that of the original mAb13 (Fig. 
4, D and C). 
Discussion 
In the present studies, we investigated the contributions 
of valency and of primary structure of V segments to the 
multiple Ag-binding of a human polyreactive IgM Ab, 
mAb55. The recombinant Ig V, and VL gene expression 
system we adopted was designed to produce a complete human 
IgG1 K molecule. Accordingly, the IgM mAb55-derived V.- 
D-J. and V~-J~ gene segments were expressed and secreted 
as a recombinant bivalent monomer (designated reclgG55), 
effectively "switching" the polyreactive IgM to IgG. On a 
weight-to-weight basis, the multiple Ag-binding of the 
reclgG55 molecule closely mimicked that of the wild-type 
IgM mAb55, showing that IgM to IgG class switch does 
not necessarily affect he characteristic feature of a polyreac- 
tive Ab, and that recognition of multiple Ags is a function 
that is absolutely restricted to the Ig V domains. This finding 
suggests that the role of natural polyreactive IgM extends 
far beyond that of providing the structural elements of the 
idiotypic regulatory network in early ontogeny, and that of 
enhancing opsonization and/or complement activation after 
binding invading microorganisms in the early phases of in- 
fection. Natural polyreactive IgM-producing cells may in- 
clude the precursors of cells producing high-affinity polyreac- 
tive IgG or IgA autoantibodies or Abs to exogenous microbial 
Ags, after undergoing an Ag-dependent process of clonal ac- 
tivation and expansion entailing class switch and, possibly, 
somatic mutation and Ag selection (8-10). 
The experiments involving the hybrid IgG molecules gener- 
ated by coexpressing the mAb55-derived H or K chain V seg- 
ment with the mAb13-derived K or H chain V segment, respec- 
tively, clearly demonstrated that the H chain plays a major 
role in mAb55 polyreactivity. This is consistent with previous 
observations that the specificity of monoreactive-specific Abs
and autoantibodies is mainly determined by the H chain V 
segment (26, 27), although in some cases the L chain seems 
to play a critical role in defining epitope specificity (28, 29). 
Individual Ig H chains can bind Ag independently of the con- 
tribution of any L chain, as originally shown by Utsumi and 
Karush (30) in an isolated rabbit H chain to p-azophenyl- 
/3-1actoside, and by Jaton et al. (31) in an isolated rabbit H 
chain to the 2,4-dinitrophenyl group. These early findings 
have recently been extended by experiments showing efficient 
Ag-binding of cloned murein V, domains, "single domain 
antibodies" to lysozyme or KLH (32), and by the observa- 
tion that a broad Ag-binding repertoire isprovided by natu- 
rally occurring Ig H chain dimers in the camel (33). Finally, 
x-ray crystallography as demonstrated in at least three Ag- 
Ab systems that the number of Ag-contacting residues in 
the H chain far exceeds that in the L chain (34, 35). 
The experiments, in which the presence or absence of the 
mAb55-derived H chain CDR3 sequence r sulted in acquisi- 
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tion or abolition, respectively, of polyreactivity, whether in 
a mAb55 or mAbl3-1ike structural context, indicated that 
the CDK3 provides acritical structural correlate for the mul- 
tiple Ag-binding activity of mAb55. The generated chimeric 
molecules satisfied the criteria set by Chothia and Lesk (26), 
i.e., they were identical in those canonical Flk sequences that 
are adjacent to the CDKs, and are critical for the full preser- 
vation of the CDR. loop structure. Thus, our choice of Abs 
and experimental design for shuffling the FK and CDR. se- 
quences should have prevented the structural deleterious effects 
which might be observed when CDtt. sequences are grafted 
onto FR contexts different from those of the original Ab 
molecule (37, 38). The H chain CDlk3 of mAb55 is excep- 
tionally long (31 amino acids), identifying a structure poten- 
tially capable of providing multiple contact interfaces, which 
may partially overlap, for different epitopes (1, 39). Crystal- 
lographic analysis has shown that at least in the case of rela- 
tively large protein Ags, multiple residues within the H chain 
CDK3 interface with Ag even in specific (monoreactive) Abs 
(35, 40, 41). However, as suggested by Chothia nd Lesk (26), 
the important role of the H chain CDR3 in Ab specificity 
may arise from the central position of this structural element 
in the binding site rather than from its sheer size (or number 
of contact residues). In at least some polyreactive Abs, a wide 
H chain CDR3 loop may be critical for accommodating 
different Ags, but relatively short H chain CDR3s have been 
reported in other human polyreactive Abs (5, 7-12). In fact, 
the H chain CDR3 structures of human polyreactive Abs 
so far described are highly divergent in length and composi- 
tion, and do not allow for the identification of any obvious 
common motif possibly responsible for polyreactivity (5-12). 
This structural heterogeneity might underlie the functional 
"uniqueness" i.e., the discrete Ag-binding features, of each 
polyreactive mAb (5, 8, 9), but at the same time it raises 
the possibility that, in certain Abs, polyreactivity is medi- 
ated primarily by structures other than the H chain CDR3. 
An important role of the H chain CDR3 in providing the 
structural correlate for multiple Ag-binding has been sug- 
gested by Harindranath etal. (6) for human RF IgM autoan- 
tibodies, by Ikematsu et al. (8) and by Kasaian et al. (10) for 
other human IgG and IgA autoantibodies, and by Chen et 
al. (13), who showed that the H chain CDR,3 was the most 
obvious parameter distinguishing polyreactive from monoreac- 
rive Ag-induced Abs in a panel of 84 murine mAbs. This 
hypothesis was substantiated by Martin et al. (14). They gener- 
ated transfectomas to pair the cross-reactive idiotype (CRI) 
17.109 + rL chain of SMI, a polyreactive IgM RF utilizing 
a CtkI G6 § VHI segment, with the Ig H chain of SMI or 
10 other nonpolyreactive IgMs. All these IgMs had G6 § H 
chains encoded by the same V~I gene as SMI, but different 
D-JH (CDR3) sequences. None of the 10 recombinant IgM 
Abs utilizing a H chain other than SMI was polyreactive, 
suggesting that the polyreactivity ofSMI was dependent on 
the structure of the H chain CDR3. Our findings trengthen 
these observations by directly demonstrating that the grafting 
of the H chain CDtk3 of a polyreactive Ig onto an originally 
monoreactive Ig results in multiple Ag-binding, and show 
further that an appropriate L chain V segment is necessary 
to fully express the polyreactive potential of the Ig H chain 
CDR3. Other L chains have been shown to not only con- 
tribute to Ag specifidty of polyreactivity but also to efficiently 
bind Ags independently of H chains. Dimers of the MOPC 
315 L chain bind e-N-(2,4 dinitrophenyl)-t.-lysine a d4-(ot- 
N-alanine)-7-nitrobenz-2-oxa-1, 3-diazide (42, 43); and dimers 
of the L chain Bence-Jones Mcg protein bind dinitrophenyl 
compounds, e-dansyUysine, colchichine, 1,10-phenanthroline, 
methadone, morphine, meperidine, 5-acetyluracil, caffeine, 
theophylline, menadione (vitamin K3), triacetin, and other 
compounds (44, 45). In the case of mAb55, the direct mul- 
tiple Ag-binding activity of the V~325 segment remains to 
be defined as this V~ segment failed to generate a polyreac- 
tive Ab when paired with the V, segment of mAbl3. The 
FR1-FR3 sequence of the mAb55-derived r chain V segment 
is identical to the FR1-FR3 sequence ofthe germline kv325 
gene, and to that of the V~ (SMI) segment used by Martin 
et al. (14) to express the polyreactivity of the SMI H chain. 
In fact, the mAb55 and SMI K chains are identical not only 
in their FR1-FR.3 sequence, but also in their FR.4 sequence, 
and in the first seven of nine amino acids of the CDR3. The 
kv325 and other closely related segments of the V~IIIb sub- 
group are frequently utilized to encode natural polyreactive 
Abs, as well as disease-associated autoantibodies, particularly 
RFs in autoimmune patients and chronic lymphocytic 
leukemia patients (20, 24, 46). The FR residues of V,IIIb 
segments, which are putatively involved in the binding of 
the IgG Fc fragment (47), may also serve in stabilizing or 
defining the multiple Ag-binding site in polyreactive Abs. 
Although limited to a single Ab pair, the present findings 
suggest that both monoreactive and polyreactive Ag-binding 
sites can be generated utilizing identical H and L chain V 
gene segments in conjunction with discrete primary struc- 
tures of the H chain CDR3 (see Fig. 4, K and L). Previous 
observations have shown that the pool of V. genes used by 
polyreactive natural Abs overlaps, at least partially, with that 
of V. genes recruited in high-affinity immune responses to 
foreign Ags in healthy subjects or to self Ags in autoimmune 
patients patients (1, 5-10, 16, 24, 48). In contrast, the H 
chain CDR3 constitutes an important source of diversity in 
the expressed Ab repertoire, since its structure results from 
complex somatic rearrangement vents, often involving more 
than one D gene in different orientations, and "unencoded" 
nucleotide additions (19, 49, 50). Computer analysis by Sanz 
(50) of more than 500 sequences from a CDR3-spedfic cDNA 
library revealed that these human Ig H chain sequences have 
the potential to generate more than 1014 different peptides. 
In view of the findings of Martin et al. (14), however, only 
a minority of somatically generated H chain CDR3s would 
give rise to Abs binding multiple Ags. The frequency of fully 
polyreactive Abs would be further educed by the require- 
ment for an appropriate L chain V segment, as shown here, 
and/or other H or L chain structures. This expected paucity 
of newly generated polyreactive Abs contrasts with the con- 
sistent findings that polyreactive Ab-producing cells account 
for up to 30% of the adult, and possibly more of the neo- 
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natal, human B cell repertoire (for a review see reference 51). 
Polyreactive Ab-producing cell precursors may be positively 
selected by contact with self Ags in early ontogeny, ina fashion 
similar to T cells in the thymus, where cells bearing receptors 
with low affinity for self Ags are recruited along the T cell 
maturation pathway (52). A somatic selection and amplifica- 
tion of human polyreactive Ab-producing cell clones would 
be further supported by the findings suggesting that most 
of the peripheral blood B cells in mice are ligand selected 
(53). The extension of combined structural and functional 
studies to other polyreactive Abs may help define the gener- 
ality of the present findings and elucidate the role of these 
Abs in development and disease. 
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